Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published 30 July 2010 Volume 2010:6 Pages 665—669

DOI http://dx.doi.org/10.2147/VHRM.S5686

Review by Single-blind

Peer reviewer comments 2

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?

Tsolaki F, Gogaki E, Sakkias F, Skatharoudi C, Lopatatzidi C, Tsoulopoulos V, Lampoura S, Topouzis F, Tsolaki M, Kountouras J

Clinical Ophthalmology 2012, 6:45-47

Published Date: 6 January 2012

Use of cross-linked carboxymethyl cellulose for soft-tissue augmentation: preliminary clinical studies

Mauro Leonardis, Andrea Palange, Rodrigo FV Dornelles, et al

Clinical Interventions in Aging 2010, 5:317-322

Published Date: 9 November 2010

Low high-density lipoprotein cholesterol: current status and future strategies for management

Vibhuti Singh, Rakesh Sharma, Ajoy Kumar, et al

Vascular Health and Risk Management 2010, 6:979-996

Published Date: 29 October 2010

Congestive heart failure in subjects with thyrotoxicosis in a black community

R C Anakwue, B J C Onwubere, B C Anisiuba, et al

Vascular Health and Risk Management 2010, 6:473-477

Published Date: 5 July 2010

Existing data sources for clinical epidemiology: The North Denmark Bacteremia Research Database

Henrik C Schønheyder, Mette Søgaard

Clinical Epidemiology 2010, 2:171-178

Published Date: 4 June 2010

Clinical characteristics and long-term response to mood stabilizers in patients with bipolar disorder and different age at onset

Bernardo Dell’Osso, Massimiliano Buoli, Riccardo Riundi, Nazario D’Urso, et al.

Neuropsychiatric Disease and Treatment 2009, 5:399-404

Published Date: 14 July 2009